| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 48 | 23.8x | 17.8x | Around median | |
Growth | 63 | 8.6% | 7.1% | Around median | |
Quality | 87 | 14.8% | 4.5% | Top tier | |
Safety | 70 | 1.4x | 2.6x | Top tier | |
Capital Return | 61 | 1.31% | 2.12% | Around median | |
Momentum | 31 | -1.0% | 2.9% | Bottom tier | |
Sentiment | 84 | 9 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
AstraZeneca PLC develops and markets innovative medicines across three main areas: Oncology, BioPharmaceuticals, and Rare Disease. Revenue comes primarily from sales of medicines such as Tagrisso, Calquence, Imfinzi, Farxiga, and Ultomiris, in addition to alliance revenue and profit sharing from partnered medicines such as Enhertu, Datroway, and Tezspire; alliance revenue increased 29% in the first half of FY 2026.
In FY 2025, revenue was $58.7 billion, gross profit was $48.1 billion, net income was $10.2 billion, and earnings per share were $6.54, equivalent to a gross margin of approximately 81.9% and a net income margin of approximately 17.4%. This compares with revenue of $54.1 billion and net income of $7.0 billion in FY 2024, and revenue of $45.8 billion and net income of $6.0 billion in FY 2023. According to EDGAR data for Q2 FY 2025, the company recorded revenue of $14.5 billion, gross profit of $12.0 billion, net income of $2.4 billion, and earnings per share of $1.57, with a gross margin of approximately 82.8%.
In the latest Q2 FY 2026 call, management announced that first-half FY 2026 revenue grew 6%, or 11% excluding the impact of Farxiga and Brilinta, which were affected by generics, while core earnings per share rose 11% and the core gross margin reached 83%. Oncology generated first-half revenue of $14.1 billion, up 15%, BioPharmaceuticals revenue was $11.2 billion, down 5%, and Rare Disease revenue grew 11% to $4.9 billion. In Q2 FY 2026, Tagrisso generated revenue of $1.9 billion, Calquence exceeded $1 billion for the first time in a single quarter, and Enhertu recorded approximately $888 million, up 31%.
The analyst consensus is “Buy,” with an average price target of $186.67 and a wide range between $158 and $216. The average target lies between the bounds of the 52-week range of $145.80 and $212.71, but below its high, while the highest target slightly exceeds that high; this dispersion reflects clear differences regarding the pipeline's ability to offset loss of exclusivity. A price-to-earnings ratio is unavailable in the data, so the consensus should be considered alongside clinical trial risks and Farxiga pressures, rather than as an independent judgment of value.
Figures in the text are as of 2026-08-26; the live price is shown at the top of the page.
The company announced on July 27, 2026, that first-half FY 2026 revenue grew 6%, or 11% excluding Farxiga and Brilinta, and core earnings per share increased 11%. The core gross margin reached 83%, with Oncology growing 15% to $14.1 billion and Rare Disease growing 11% to $4.9 billion in the first half. In Q2 FY 2026, Tagrisso generated revenue of $1.9 billion and Calquence exceeded $1 billion, while Enhertu recorded approximately $888 million.
Yes, management confirmed in the July 27, 2026, call that the $80 billion revenue ambition by 2030 remains in place. It explained that the estimate is risk-adjusted and assumes that some programs succeed and others fail, rather than relying on a single asset. The plan is supported by six positive results from key Phase III programs during the first half of FY 2026 and 25 key readouts planned over 18 months from the date of the call.
In Oncology, Enhertu grew 31% to $888 million in Q2 FY 2026, Calquence exceeded $1 billion for the first time, and Tagrisso generated revenue of $1.9 billion. In Respiratory, Tezspire grew 45% to $390 million, Fasenra grew 13% to $570 million, and Breztri grew 20% to $346 million. Management believes that Datroway, Etcamah, and Baxfendy each have the potential to exceed $5 billion in peak annual revenue and also raised the estimate for tozorakimab to more than $5 billion.
Automated analysis for informational purposes only — not investment advice.
BioPharmaceuticals revenue declined 5% to $11.2 billion in the first half of FY 2026 due to Farxiga, Brilinta, and roxadustat. In Q2 FY 2026, Farxiga declined 19% to $1.8 billion after generic competition entered the United States, and Symbicort declined 8% to $671 million following the entry of a new generic competitor. In contrast, total revenue growth was 11% excluding Farxiga and Brilinta, illustrating the strength of the rest of the portfolio but not eliminating the pressure from loss of exclusivity.
Reports emerged on August 3, 2026, about preliminary talks that could result in an entity valued at approximately $400 billion, but they did not constitute an announcement of a confirmed deal within the data. On August 4, 2026, reports pointed to potential regulatory obstacles in Oncology and doubts from Jefferies about using AstraZeneca shares in the acquisition. Jim Cramer also questioned the accuracy of the rumors, so this news remains a source of volatility rather than an established financial basis for the deal.
The data indicate one sale and no purchases during the three months ending with the transaction recorded on May 20, 2026, for net sales of $2.2 million. This is a weak signal on its own because insider sales may be prearranged, and the data do not clarify whether this transaction was. It is less important than FY 2025 revenue growth to $58.7 billion and the risks from the loss of Farxiga exclusivity and clinical trial results in FY 2026.
